Drug and medical-device companies in Indiana lauded the passage of the Senate health reform bill, expressing satisfaction with certain amendments that would reduce costs to be shouldered by the industries. Lawmakers decided not to include a measure on drug reimportation and also reduced from $40 billion to $20 billion a proposed tax that would have been imposed on device makers.

Related Summaries